ArticleStem cell research & therapy2025
Generation of hTERT-immortalized human mesenchymal stromal cells with optical and magnetic labels for in vivo transplantation and tracking.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMesenchymal stem/stromal cells (MSCs) are the focus of increasing research as a potential therapeutic agent for a range of nervous system diseases, due to their unique capacity for self-renewal and differentiation. The subsequent tracking of cells post-transplantation into the organism is of pivotal significance, as it elucidates their fate, distribution, and enables the timely monitoring of any adverse effects. In the context of cell monitoring, the utilization of a non-toxic label that exhibits long-term stability is of paramount importance.
methodsA human immortalized MSCs cell line was engineered to express a green fluorescent protein (GFP) and bacterial nanocompartments (high-molecular-weight icosahedral capsid-like protein complexes) via lentiviral transduction. The obtained cells were characterized by inductively coupled plasma mass spectrometry (ICP-MS) and Perls staining as well as using the nonlinear magnetization method, confocal microscopy and flow cytometry. An animal study was conducted in Sprague-Dawley rats.
resultsIn this study, an immortalized human MSCs cell line with stable expression of a novel magnetic resonance (MR) reporter label was established for the first time. GFP was genetically produced for utilization as an optical tag. A nanocompartment of the bacterium Quasibacillus thermotolerans (Qt) was used as a carrier of the magnetic label. The Qt nanocompartment consists of a shell and a ferroxidase cargo protein. Ferroxidase provides the biomineralization of iron ions within the nanocompartment shell. As a result, ferric oxide nanoparticles are formed inside the encapsulin nanocompartments, which have T2-contrast properties and serve as genetically encoded labels for magnetic resonance imaging (MRI) and for quantification by the nonlinear magnetization method.
conclusionsThe experimental results indicate that the use of two complementary labels allows for the multimodal visualization of the derived cells post-transplantation into the rat brain striatum, which is promising for monitoring MSCs-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.